
TMO Valuation
Thermo Fisher Scientific Inc
- Overview
- Forecast
- Valuation
- Earnings
TMO Relative Valuation
TMO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TMO is overvalued; if below, it's undervalued.
Historical Valuation
Thermo Fisher Scientific Inc (TMO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 20.39 is considered Undervalued compared with the five-year average of 24.16. The fair price of Thermo Fisher Scientific Inc (TMO) is between 566.05 to 672.56 according to relative valuation methord. Compared to the current price of 478.32 USD , Thermo Fisher Scientific Inc is Undervalued By 15.5%.
Relative Value
Fair Zone
566.05-672.56
Current Price:478.32
15.5%
Undervalued
20.39
PE
1Y
3Y
5Y
Trailing
Forward
18.47
EV/EBITDA
Thermo Fisher Scientific Inc. (TMO) has a current EV/EBITDA of 18.47. The 5-year average EV/EBITDA is 20.67. The thresholds are as follows: Strongly Undervalued below 16.49, Undervalued between 16.49 and 18.58, Fairly Valued between 22.77 and 18.58, Overvalued between 22.77 and 24.86, and Strongly Overvalued above 24.86. The current Forward EV/EBITDA of 18.47 falls within the Undervalued range.
20.38
EV/EBIT
Thermo Fisher Scientific Inc. (TMO) has a current EV/EBIT of 20.38. The 5-year average EV/EBIT is 22.69. The thresholds are as follows: Strongly Undervalued below 17.84, Undervalued between 17.84 and 20.27, Fairly Valued between 25.12 and 20.27, Overvalued between 25.12 and 27.55, and Strongly Overvalued above 27.55. The current Forward EV/EBIT of 20.38 falls within the Historic Trend Line -Fairly Valued range.
4.03
PS
Thermo Fisher Scientific Inc. (TMO) has a current PS of 4.03. The 5-year average PS is 5.03. The thresholds are as follows: Strongly Undervalued below 3.83, Undervalued between 3.83 and 4.43, Fairly Valued between 5.63 and 4.43, Overvalued between 5.63 and 6.22, and Strongly Overvalued above 6.22. The current Forward PS of 4.03 falls within the Undervalued range.
19.34
P/OCF
Thermo Fisher Scientific Inc. (TMO) has a current P/OCF of 19.34. The 5-year average P/OCF is 22.20. The thresholds are as follows: Strongly Undervalued below 16.37, Undervalued between 16.37 and 19.28, Fairly Valued between 25.11 and 19.28, Overvalued between 25.11 and 28.02, and Strongly Overvalued above 28.02. The current Forward P/OCF of 19.34 falls within the Historic Trend Line -Fairly Valued range.
17.95
P/FCF
Thermo Fisher Scientific Inc. (TMO) has a current P/FCF of 17.95. The 5-year average P/FCF is 27.54. The thresholds are as follows: Strongly Undervalued below 18.31, Undervalued between 18.31 and 22.93, Fairly Valued between 32.15 and 22.93, Overvalued between 32.15 and 36.76, and Strongly Overvalued above 36.76. The current Forward P/FCF of 17.95 falls within the Strongly Undervalued range.
Thermo Fisher Scientific Inc (TMO) has a current Price-to-Book (P/B) ratio of 3.58. Compared to its 3-year average P/B ratio of 4.52 , the current P/B ratio is approximately -20.84% higher. Relative to its 5-year average P/B ratio of 4.98, the current P/B ratio is about -28.00% higher. Thermo Fisher Scientific Inc (TMO) has a Forward Free Cash Flow (FCF) yield of approximately 3.42%. Compared to its 3-year average FCF yield of 3.31%, the current FCF yield is approximately 3.09% lower. Relative to its 5-year average FCF yield of 3.34% , the current FCF yield is about 2.36% lower.
3.58
P/B
Median3y
4.52
Median5y
4.98
3.42
FCF Yield
Median3y
3.31
Median5y
3.34
Competitors Valuation Multiple
The average P/S ratio for TMO's competitors is 7.32, providing a benchmark for relative valuation. Thermo Fisher Scientific Inc Corp (TMO) exhibits a P/S ratio of 4.03, which is -44.97% above the industry average. Given its robust revenue growth of 2.98%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TMO decreased by 21.91% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 10.54B to 10.86B.
The secondary factor is the Margin Expansion, contributed 1.15%to the performance.
Overall, the performance of TMO in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch

PEP
PepsiCo Inc
143.450
USD
-0.73%

KO
Coca-Cola Co
69.170
USD
+0.10%

TSM
Taiwan Semiconductor Manufacturing Co Ltd
245.600
USD
+1.66%

ACN
Accenture PLC
283.150
USD
+0.51%

ABBV
AbbVie Inc
190.280
USD
-0.29%

ADBE
Adobe Inc
370.740
USD
-0.26%

NFLX
Netflix Inc
1180.490
USD
-0.02%

CMCSA
Comcast Corp
33.680
USD
-4.78%

BAC
Bank of America Corp
48.450
USD
+0.12%

BRK.A
Berkshire Hathaway Inc
726220.000
USD
+0.07%
FAQ

Is Thermo Fisher Scientific Inc (TMO) currently overvalued or undervalued?
Thermo Fisher Scientific Inc (TMO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 20.39 is considered Undervalued compared with the five-year average of 24.16. The fair price of Thermo Fisher Scientific Inc (TMO) is between 566.05 to 672.56 according to relative valuation methord. Compared to the current price of 478.32 USD , Thermo Fisher Scientific Inc is Undervalued By 15.50% .

What is Thermo Fisher Scientific Inc (TMO) fair value?

How does TMO's valuation metrics compare to the industry average?

What is the current P/B ratio for Thermo Fisher Scientific Inc (TMO) as of Jul 28 2025?

What is the current FCF Yield for Thermo Fisher Scientific Inc (TMO) as of Jul 28 2025?

What is the current Forward P/E ratio for Thermo Fisher Scientific Inc (TMO) as of Jul 28 2025?
